Indivior PLC announces a business update. The Group will immediately cease all sales and marketing activities related to PERSERIS. The Group believes this action is in the best interests of shareholders due to the highly competitive market and impending changes that are expected to intensify payor management in the treatment category in which PERSERIS participates.

Analysis of forthcoming changes suggests that there is no longer a path forward for PERSERIS that is financially viable. Indivior will continue to supply PERSERIS for the foreseeable future to avoid disruption to patient care but will no longer deploy a dedicated sales force. As a result, the company expects to reduce headcount by approximately 130 employees.

Indivior does not anticipate material impacts on its other marketed products because of this decision. Total expected charges related to this action are expected to be approximately $65 million, of which approximately $20 million are expected to be cash related to severance and termination of certain agreements. These charges will be recognized in the second and third quarters and excluded from adjusted earnings.

Ongoing annual operating expense savings are expected to be approximately $50 million, with $20 million expected to be realized in H2 2024.